Carina Biotech submits LGR5 CAR-T pre-IND (Investigational New Drug) package to the US Food & Drug Administration
Carina Biotech is very pleased to announce that we have submitted a pre-IND (Investigational New Drug) application to the US FDA (Food
5 Biggest Biotech Trends in 2022
In Forbes' 5 Biggest Biotech Trends for 2022, top of the list is personalised medicine – of which CAR-T therapy
Carina Biotech licenses German technology to create highly efficient CAR-T cells targeting hard-to-treat cancers
Carina Biotech has entered a license agreement with Bayerische Patentallianz (BayPAT) to the CXCR6-transduced CAR-T cell technology developed at the
Manufacture of Carina’s LGR5 CAR-T has begun with CellVec contracted to produce GMP-grade lentivirus constructs
Singapore-based CellVec will manufacture clinical-grade lentivirus – the first critical step in making LGR5 CAR-T cells for a first-in-human clinical
Carina Biotech raises $5.4 million to ready LGR5 CAR-T program for advanced colorectal cancer for the clinic
Carina Biotech is delighted to announce it has raised AU$5.4 million. The raise was strongly supported by current shareholders, board and
Carina Biotech and AdAlta to develop unique next-generation CAR-T cancer therapeutics
Carina Biotech has entered a collaboration agreement with Melbourne biotech AdAlta to develop precision engineered, i-body enabled CAR-T therapies that provide
Carina researcher Jade Foeng joins Carina Biotech corporate team
We are very pleased to welcome to our corporate team Jade Foeng, researcher & PhD student in Professor Shaun McColl's lab
Carina Biotech is pleased to announce its newly appointed Medical Advisory Board
Carina Biotech's four-member Medical Advisory Board will advise us as we prepare to take our LGR5-targeted CAR-T cell for advanced